Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03741426
Title WIRE - Novel Treatments in Renal Cell Cancer (WIRE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors CCTU- Cancer Theme
Indications

clear cell renal cell carcinoma

Therapies

Durvalumab

Cediranib

Durvalumab + Olaparib

Cediranib + Olaparib

Olaparib

Age Groups: senior | adult
Covered Countries


No variant requirements are available.